Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
Autor: | Orsolya Nagy, Aozhou Wu, A. Ostor, Ruta Sawant, Keith A. Betts, Cynthia Z. Qi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Economic benefit Remission Cost-Benefit Analysis Review Direct cost Efficiency Arthritis Rheumatoid Indirect costs Quality of life Internal medicine Health care Healthcare resource utilization medicine Humans Pharmacology (medical) Rheumatoid arthritis Intensive care medicine Productivity Reimbursement business.industry General Medicine Health Care Costs Patient Acceptance of Health Care medicine.disease Rheumatology Indirect cost Antirheumatic Agents Value (economics) Quality of Life business Treat-to-target |
Zdroj: | Advances in Therapy |
ISSN: | 1865-8652 0741-238X |
Popis: | The treat-to-target strategy, which defines clinical remission as the primary therapeutic goal for rheumatoid arthritis (RA), is a widely recommended treatment approach in clinical guidelines. Achieving remission has been associated with improved clinical outcomes, quality of life, and productivity. These benefits are likely to translate to reduced economic burden in terms of lower healthcare costs and resource utilization. As such, a literature review was conducted to better understand the economic value of remission. Despite the large heterogeneity found in RA-related economic outcomes across studies, patients in remission consistently had lower direct medical and indirect costs, less healthcare resource utilization, and greater productivity compared to those without remission. Remission was associated with 19–52% savings in direct medical costs and 37–75% savings in indirect costs. The economic value of remission should thus be considered in economic analyses of RA therapies to inform treatment and reimbursement decisions. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01946-w. |
Databáze: | OpenAIRE |
Externí odkaz: |